The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure

Pharmacological Research

Volumn 74, Issue , 2013, Pages 49-55

  Flierl, Ulrike ^a   Fraccarollo, Daniela ^a   Micka, Jan ^b   Bauersachs, Johann ^a   Schäfer, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Congestive heart failure; Direct FXa inhibitor; Platelet activation; Rivaroxaban

Indexed keywords

CD11B ANTIGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; RIVAROXABAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INTERACTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

BOVINE SERUM ALBUMIN; BSA; CHF; CONGESTIVE HEART FAILURE; DIMETHYL SULFOXIDE; DIRECT FXA INHIBITOR; DMSO; FACTOR X; FITC; FLUORESCEIN ISOTHIOCYANATE; FX; G-PROTEIN COUPLED RECEPTOR; GPCR; LEFT VENTRICULAR END-DIASTOLIC PRESSURE; LVEDP; MEAN FLUORESCENCE INTENSITY; MFI; PBS; PHOSPHATE-BUFFERED SALINE; PLA; PLATELET ACTIVATION; PLATELET-LEUKOCYTE AGGREGATES; PLATELET-MONOCYTE AGGREGATES; PLATELET-RICH PLASMA; PMA; PRP; RIVAROXABAN; TF; TISSUE FACTOR; WB; WHOLE BLOOD;

ANIMALS; ANTICOAGULANTS; FACTOR XA; HEART FAILURE; HUMANS; MALE; MORPHOLINES; PLATELET ACTIVATION; PLATELET AGGREGATION; RATS; RATS, WISTAR; THIOPHENES;

EID: 84884810052     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.05.002     Document Type: Article

References (40)

1. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, and K. Dickstein ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the esc European Heart Journal 33 2012 1787 1847
2. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, and T.G. Ganiats 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the international society for heart and lung transplantation Journal of the American College of Cardiology 53 2009 e1 e90
3. B.S. Chin, D.S. Conway, N.A. Chung, A.D. Blann, C.R. Gibbs, and G.Y. Lip Interleukin-6, tissue factor and von willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis Blood Coagulation and Fibrinolysis 14 2003 515 521 (Pubitemid 37083165)
4. M. Koksch, F. Zeiger, K. Wittig, A. Siegemund, C.B. Reininger, and D. Pfeiffer Coagulation, fibrinolysis and platelet p-selectin expression in peripheral vascular disease European Journal of Vascular and Endovascular Surgery 21 2001 147 154 (Pubitemid 32243908)
5. P.A. Gurbel, D.J. Kereiakes, M.R. Dalesandro, R.D. Bahr, C.M. O'Connor, and V.L. Serebruany Role of soluble and platelet-bound p-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department American Heart Journal 139 2000 320 328 (Pubitemid 30090810)
6. M. Yamazaki, S. Uchiyama, and M. Iwata Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction Thrombosis Research 104 2001 197 205 (Pubitemid 32973761)
7. W.H. Cerwinka, and D.N. Granger Influence of hypercholesterolemia and hypertension on ischemia-reperfusion induced p-selectin expression Atherosclerosis 154 2001 337 344 (Pubitemid 32146606)
8. A.D. Blann, S. Nadar, and G.Y. Lip Pharmacological modulation of platelet function in hypertension Hypertension 42 2003 1 7 (Pubitemid 36842228)
9. S.M. Ouvina, R.D. La Greca, N.L. Zanaro, L. Palmer, and B. Sassetti Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type ii patients Thrombosis Research 102 2001 107 114 (Pubitemid 32373219)
10. C.R. Gibbs, A.D. Blann, R.D. Watson, and G.Y. Lip Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy Circulation 103 2001 1746 1751 (Pubitemid 32291411)
11. A. Schafer, D. Fraccarollo, S. Hildemann, M. Christ, M. Eigenthaler, and A. Kobsar Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ace inhibition Thrombosis and Haemostasis 89 2003 1024 1030 (Pubitemid 36798154)
12. E. Loh, M.S. Sutton, C.C. Wun, J.L. Rouleau, G.C. Flaker, and S.S. Gottlieb Ventricular dysfunction and the risk of stroke after myocardial infarction New England Journal of Medicine 336 1997 251 257 (Pubitemid 27044626)
13. N. Mackman, R.E. Tilley, and N.S. Key Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis Arteriosclerosis, Thrombosis, and Vascular Biology 27 2007 1687 1693 (Pubitemid 47207163)
14. P.C. Wong, and X. Jiang Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin Thrombosis and Haemostasis 104 2010 302 310
15. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty New England Journal of Medicine 358 2008 2776 2786 (Pubitemid 351930852)
16. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty New England Journal of Medicine 358 2008 2765 2775 (Pubitemid 351930851)
17. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus Oral rivaroxaban for symptomatic venous thromboembolism New England Journal of Medicine 363 2010 2499 2510
18. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation New England Journal of Medicine 365 2011 883 891
19. H.R. Buller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, and E. Minar Oral rivaroxaban for the treatment of symptomatic pulmonary embolism New England Journal of Medicine 366 2012 1287 1297
20. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome New England Journal of Medicine 366 2012 9 19
21. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent bay 59-7939 - an oral, direct factor Xa inhibitor Journal of Thrombosis and Haemostasis 3 2005 514 521 (Pubitemid 41632877)
22. J. Graff, N. von Hentig, F. Misselwitz, D. Kubitza, M. Becka, and H.K. Breddin Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity Journal of Clinical Pharmacology 47 2007 1398 1407 (Pubitemid 47624591)
23. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Rivaroxaban (bay 59-7939) - an oral, direct factor Xa inhibitor - has no clinically relevant interaction with naproxen British Journal of Clinical Pharmacology 63 2007 469 476 (Pubitemid 46426627)
24. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin Journal of Clinical Pharmacology 46 2006 981 990 (Pubitemid 44215062)
25. D. Fraccarollo, K. Hu, P. Galuppo, P. Gaudron, and G. Ertl Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling Circulation 96 1997 3963 3973
26. J. Bauersachs, P. Galuppo, D. Fraccarollo, M. Christ, and G. Ertl Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction Circulation 104 2001 982 985 (Pubitemid 32803872)
27. A.M. van der Laan, A. Hirsch, L.F. Robbers, R. Nijveldt, I. Lommerse, and R. Delewi A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction American Heart Journal 163 2012 57 65 e52
28. J.P. Herault, F. Dol, C. Gaich, A. Bernat, and J.M. Herbert Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat Thrombosis and Haemostasis 81 1999 957 960 (Pubitemid 29312715)
29. A. Zillmann, T. Luther, I. Muller, M. Kotzsch, M. Spannagl, and T. Kauke Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation Biochemical and Biophysical Research Communications 281 2001 603 609 (Pubitemid 32928197)
30. P.C. Wong, E.J. Crain, B. Xin, R.R. Wexler, P.Y. Lam, and D.J. Pinto Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies Journal of Thrombosis and Haemostasis 6 2008 820 829 (Pubitemid 351524543)
31. S. Kim, C. Foster, A. Lecchi, T.M. Quinton, D.M. Prosser, and J. Jin Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling Blood 99 2002 3629 3636 (Pubitemid 34534532)
32. 2+ mobilization and synergistic p2y12 receptor activation Journal of Biological Chemistry 281 2006 26665 26674 (Pubitemid 44401875)
33. S.M. Jafri Hypercoagulability in heart failure Seminars in Thrombosis and Hemostasis 23 1997 543 545 (Pubitemid 28114051)
34. J. Steffel, T.F. Luscher, and F.C. Tanner Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications Circulation 113 2006 722 731
35. B.S. Chin, A.D. Blann, C.R. Gibbs, N.A. Chung, D.G. Conway, and G.Y. Lip Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure European Journal of Clinical Investigation 33 2003 941 948 (Pubitemid 37421591)
36. D. Girelli, C. Russo, P. Ferraresi, O. Olivieri, M. Pinotti, and S. Friso Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease New England Journal of Medicine 343 2000 774 780
37. A.T. Cohen, T.E. Spiro, H.R. Buller, L. Haskell, D. Hu, and R. Hull Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: Magellan study protocol Journal of Thrombosis and Thrombolysis 31 2011 407 416
38. A.T. Cohen, T.E. Spiro, H.R. Buller, L. Haskell, D. Hu, and R. Hull Rivaroxaban vs. enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: Magellan subgroup analyses Journal of Thrombosis and Haemostasis 9 2011 21
39. M. Gheorghiade, A. Thyssen, R. Zolynas, V.K. Nadar, B.H. Greenberg, and M. Mehra Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure Journal of Heart and Lung Transplantation 30 2011 218 226
40. S. van Diepen, A. Hellkamp, M. Patel, R. Becker, G. Breithardt, and J. Halperin Rivaroxaban is associated with a reduced risk of thromboembolic events and hemorrhagic stroke in patients with heart failure: insights from ROCKET-AF 2012 [AHA abstract 14365]